Cardiomyocyte injury to transplant

pediatric management.

Gul H. Dadlani, William G. Harmon, Valeriano C. Simbre, Svjetlana Tisma-Dupanovic, Steven E Lipshultz

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Cardiomyocyte injury in pediatric patients has a vast number of causes, which are often distinct from the causes of adult heart failure. However, the management of pediatric heart failure and heart transplantation has generally been inferred from adult studies. New therapies show great promise for the neurohormonal regulation of heart failure and the ability to control immunosuppression after heart transplantation. Large, randomized, multicenter, controlled clinical trials are needed to determine the efficacy of these therapies in this population. This article reviews the current recommendations and evidence-based medicine, where available, for the medical management of myopathic dysfunction and transplantation in pediatric patients.

Original languageEnglish
Pages (from-to)91-97
Number of pages7
JournalCurrent Opinion in Cardiology
Volume18
Issue number2
StatePublished - Mar 1 2003
Externally publishedYes

Fingerprint

Cardiac Myocytes
Heart Failure
Heart Transplantation
Pediatrics
Transplants
Wounds and Injuries
Evidence-Based Medicine
Immunosuppression
Randomized Controlled Trials
Transplantation
Therapeutics
Population

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Dadlani, G. H., Harmon, W. G., Simbre, V. C., Tisma-Dupanovic, S., & Lipshultz, S. E. (2003). Cardiomyocyte injury to transplant: pediatric management. Current Opinion in Cardiology, 18(2), 91-97.

Cardiomyocyte injury to transplant : pediatric management. / Dadlani, Gul H.; Harmon, William G.; Simbre, Valeriano C.; Tisma-Dupanovic, Svjetlana; Lipshultz, Steven E.

In: Current Opinion in Cardiology, Vol. 18, No. 2, 01.03.2003, p. 91-97.

Research output: Contribution to journalArticle

Dadlani, GH, Harmon, WG, Simbre, VC, Tisma-Dupanovic, S & Lipshultz, SE 2003, 'Cardiomyocyte injury to transplant: pediatric management.', Current Opinion in Cardiology, vol. 18, no. 2, pp. 91-97.
Dadlani GH, Harmon WG, Simbre VC, Tisma-Dupanovic S, Lipshultz SE. Cardiomyocyte injury to transplant: pediatric management. Current Opinion in Cardiology. 2003 Mar 1;18(2):91-97.
Dadlani, Gul H. ; Harmon, William G. ; Simbre, Valeriano C. ; Tisma-Dupanovic, Svjetlana ; Lipshultz, Steven E. / Cardiomyocyte injury to transplant : pediatric management. In: Current Opinion in Cardiology. 2003 ; Vol. 18, No. 2. pp. 91-97.
@article{0b67256b38a64eaca9058a7ae508caad,
title = "Cardiomyocyte injury to transplant: pediatric management.",
abstract = "Cardiomyocyte injury in pediatric patients has a vast number of causes, which are often distinct from the causes of adult heart failure. However, the management of pediatric heart failure and heart transplantation has generally been inferred from adult studies. New therapies show great promise for the neurohormonal regulation of heart failure and the ability to control immunosuppression after heart transplantation. Large, randomized, multicenter, controlled clinical trials are needed to determine the efficacy of these therapies in this population. This article reviews the current recommendations and evidence-based medicine, where available, for the medical management of myopathic dysfunction and transplantation in pediatric patients.",
author = "Dadlani, {Gul H.} and Harmon, {William G.} and Simbre, {Valeriano C.} and Svjetlana Tisma-Dupanovic and Lipshultz, {Steven E}",
year = "2003",
month = "3",
day = "1",
language = "English",
volume = "18",
pages = "91--97",
journal = "Current Opinion in Cardiology",
issn = "0268-4705",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Cardiomyocyte injury to transplant

T2 - pediatric management.

AU - Dadlani, Gul H.

AU - Harmon, William G.

AU - Simbre, Valeriano C.

AU - Tisma-Dupanovic, Svjetlana

AU - Lipshultz, Steven E

PY - 2003/3/1

Y1 - 2003/3/1

N2 - Cardiomyocyte injury in pediatric patients has a vast number of causes, which are often distinct from the causes of adult heart failure. However, the management of pediatric heart failure and heart transplantation has generally been inferred from adult studies. New therapies show great promise for the neurohormonal regulation of heart failure and the ability to control immunosuppression after heart transplantation. Large, randomized, multicenter, controlled clinical trials are needed to determine the efficacy of these therapies in this population. This article reviews the current recommendations and evidence-based medicine, where available, for the medical management of myopathic dysfunction and transplantation in pediatric patients.

AB - Cardiomyocyte injury in pediatric patients has a vast number of causes, which are often distinct from the causes of adult heart failure. However, the management of pediatric heart failure and heart transplantation has generally been inferred from adult studies. New therapies show great promise for the neurohormonal regulation of heart failure and the ability to control immunosuppression after heart transplantation. Large, randomized, multicenter, controlled clinical trials are needed to determine the efficacy of these therapies in this population. This article reviews the current recommendations and evidence-based medicine, where available, for the medical management of myopathic dysfunction and transplantation in pediatric patients.

UR - http://www.scopus.com/inward/record.url?scp=0038148351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038148351&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 91

EP - 97

JO - Current Opinion in Cardiology

JF - Current Opinion in Cardiology

SN - 0268-4705

IS - 2

ER -